Point72 Asset Management
KROS icon

Point72 Asset Management’s Keros Therapeutics KROS Stock Holding History

Point72 Asset Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.2M Buy
109,015
+70,167
+181% +$1.08M ﹤0.01% 2641
2025
Q4 		$791K Buy
+38,848
New +$682K ﹤0.01% 2998
2025
Q2 		– Sell
-6
Closed -$59 – 2422
2025
Q1 		$59 Sell
6
-1,586
-100% -$18.4K ﹤0.01% 1984
2024
Q4 		$25.2K Sell
1,592
-945,978
-100% -$49.2M ﹤0.01% 2018
2024
Q3 		$55M Buy
947,570
+577,220
+156% +$28.5M 0.14% 170
2024
Q2 		$16.9M Sell
370,350
-601,531
-62% -$32.3M 0.04% 445
2024
Q1 		$64.3M Buy
971,881
+890,651
+1,096% +$52.8M 0.16% 140
2023
Q4 		$3.23M Sell
81,230
-68,503
-46% -$2.15M 0.01% 1064
2023
Q3 		$4.77M Sell
149,733
-199,927
-57% -$7.46M 0.01% 893
2023
Q2 		$14M Buy
349,660
+144,000
+70% +$6.31M 0.04% 492
2023
Q1 		$8.78M Sell
205,660
-314,876
-60% -$15.9M 0.03% 581
2022
Q4 		$25M Buy
520,536
+428,696
+467% +$20M 0.09% 283
2022
Q3 		$3.46M Buy
+91,840
New +$3.18M 0.01% 821
2022
Q1 		– Sell
-63,028
Closed -$3.69M – 1285
2021
Q4 		$3.69M Sell
63,028
-85,572
-58% -$4.27M 0.01% 734
2021
Q3 		$5.88M Sell
148,600
-254,007
-63% -$9.04M 0.03% 628
2021
Q2 		$17.1M Buy
402,607
+179,445
+80% +$9.72M 0.08% 321
2021
Q1 		$13.7M Buy
223,162
+9,362
+4% +$593K 0.06% 349
2020
Q4 		$15.1M Buy
213,800
+133,000
+165% +$8.38M 0.07% 346
2020
Q3 		$3.12M Sell
80,800
-71,500
-47% -$2.84M 0.02% 645
2020
Q2 		$5.71M Buy
+152,300
New +$4.69M 0.04% 457

Other funds holding KROS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Point72 Asset Management's KROS Position: Q1 2026 in Review

Point72 Asset Management increased its Keros Therapeutics (KROS) stake by 181% in Q1 2026, buying an estimated $1.08M and bringing the position to 109,015 shares worth $1.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2641.

Point72 Asset Management first reported a position in KROS in Q2 2020 and has held it in 20 quarters since. The position peaked at $64.3M in Q1 2024. 151 funds tracked by Wall St. Rank hold KROS as of Q1 2026.

  • Point72 Asset Management held 109,015 shares of Keros Therapeutics worth $1.2M as of Q1 2026.
  • Point72 Asset Management bought 70,167 Keros Therapeutics shares in Q1 2026, an estimated $1.08M.
  • Keros Therapeutics made up ﹤0.01% of Point72 Asset Management's portfolio in Q1 2026, its #2641 holding.
  • Point72 Asset Management first reported a position in Keros Therapeutics in Q2 2020 and has held it in 20 quarters since.
  • Point72 Asset Management's Keros Therapeutics position peaked at $64.3M in Q1 2024.
  • 151 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.